Abstract
Objective
To describe the presentation of giant cell tumors (GCT) of the bone in the pediatric population to (1) improve the differential diagnosis of pediatric bone tumors and (2) identify the origin of GCT. Understanding the origin of bone tumors assists in establishing appropriate diagnoses and recommending treatment options. This is particularly important in children, where evaluating the need for invasive procedures is balanced with the desire to avoid overtreatment. GCT have historically been considered epiphyseal lesions with potential metaphyseal extension. Therefore, GCT may be inappropriately excluded from the differential diagnosis of metaphyseal lesions in the skeletally immature.
Materials and methods
We identified 14 patients from 1981 to 2021 at a single institution who had histologic confirmation of GCT and were less than 18 years old at diagnosis. Patient characteristics, tumor location, surgical treatment, and local recurrence rates were collected.
Results and conclusions
Ten (71%) patients were female. Eleven (78.6%) were epiphysiometaphyseal (1 epiphyseal, 4 metaphyseal, 6 epiphysiometaphyseal). Five patients had an open adjacent physis, of which three (60%) had tumors confined solely to the metaphysis. Of the five patients with open physis, four (80%) developed local recurrence while only one patient (11%) with a closed physis had local recurrence (p value = 0.0023). Our results illustrate that for the skeletally immature, GCT can (and in our results more commonly did) occur in the metaphyseal location. These findings suggest that GCT should be included in the differential diagnosis of primary metaphyseal-only lesions in the skeletally immature.
Similar content being viewed by others
References
Murphey MD, Nomikos GC, Flemming DJ, Gannon FH, Temple HT, Kransdorf MJ. From the archives of AFIP Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. Radiographics. 2001;21(5):1283–309.
Liede A, Hernandez RK, Tang E, Li C, Bennett B, Wong SS, et al. Epidemiology of benign giant cell tumor of bone in the Chinese population. J Bone Oncol. 2018;12:96–100.
Verschoor AJ, Bovée J, Mastboom MJL, Sander Dijkstra PD, Van De Sande MAJ, Gelderblom H. Incidence and demographics of giant cell tumor of bone in The Netherlands: first nationwide Pathology Registry Study. Acta Orthop. 2018;89(5):570–4.
Burke C, Link T, O’Donnell RJ, Cho SJ, Motamedi D. Giant cell tumor of bone: documented progression over 4 years from its origin at the metaphysis to the articular surface. Case Rep Radiol. 2016;2016:9786925.
Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Giant cell tumor of bone. Am J Clin Oncol. 2006;29:96–9.
Çomunoğlu N, Kepil N, Dervışoğlu S. Histopathology of giant cell tumors of the bone: with special emphasis on fibrohistiocytic and aneurysmal bone cyst like components. Acta Orthop Traumatol Turc. 2019;53:35–9.
Wülling M, Engels C, Jesse N, Werner M, Delling G, Kaiser E. The nature of giant cell tumor of bone. J Cancer Res Clin Oncol. 2001;127(8):467–74.
Sharma V, Sharma S, Mistry KA, Awasthi B, Verma L, Singh U. Giant cell tumor of bone in skeletally immature patients - a clinical perspective. J Orthop Case Rep. 2015;5(4):57–60.
Hoeffel JC, Galloy MA, Grignon Y, Chastagner P, Floquet J, Mainard L, et al. Giant cell tumor of bone in children and adolescents. Rev Rhum Engl Ed. 1996;63(9):618–23.
Strøm TM, Skeie AT, Lobmaier IK, Zaikova O. Giant cell tumor: a rare condition in the immature skeleton-a retrospective study of symptoms, treatment, and outcome in 16 children. Sarcoma. 2016;2016:3079835.
Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics. 2013;33(1):197–211.
Huvos AG. Bone tumors: Diagnosis, treatment and prognosis. 2nd ed. United States: WB Saunders CBS Educ and Professional Publ; 1987.
Picci P, Manfrini M, Zucchi V, Gherlinzoni F, Rock M, Bertoni F, et al. Giant-cell tumor of bone in skeletally immature patients. J Bone Joint Surg Am. 1983;65(4):486–90.
Puri A, Agarwal MG, Shah M, Jambhekar NA, Anchan C, Behle S. Giant cell tumor of bone in children and adolescents. J Pediatr Orthop. 2007;27(6):635–9.
Goldenberg RR, Campbell CJ, Bonfiglio M. Giant-cell tumor of bone An analysis of two hundred and eighteen cases. J Bone Joint Surg Am. 1970;52(4):619–64.
Khatri K, Singh J, Kalia A, Dahuja A. Giant cell tumour of clavicle: occurrence of a common tumour in a rare location. Int J Surg Case Rep. 2016;29:51–5.
Kim WJ, Kim S, Choi DW, Lim GH, Jung ST. Characteristics of giant cell tumor of the bone in pediatric patients: our 18-year, single-center experience. Children (Basel). 2021; 8(12)
Nagano S, Tsuchimochi T, Yokouchi M, Setoguchi T, Sasaki H, Shimada H, et al. Giant cell tumor of the clavicle: report of a case in a rare location with consideration of surgical method. BMC Musculoskelet Disord. 2015;16:142.
Ogura K, Higashi T, Kawai A. Statistics of soft-tissue sarcoma in Japan: report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci. 2017;22(4):755–64.
Hughes JL, Newton PO, Bastrom T, Fabricant PD, Pennock AT. The clavicle continues to grow during adolescence and early adulthood. Hss j. 2020;16(Suppl 2):372–7.
Dahlin DC. Caldwell Lecture Giant cell tumor of bone: highlights of 407 cases. AJR Am J Roentgenol. 1985;144(5):955–60.
Futamura N, Urakawa H, Tsukushi S, Arai E, Kozawa E, Ishiguro N, et al. Giant cell tumor of bone arising in long bones possibly originates from the metaphyseal region. Oncol Lett. 2016;11(4):2629–34.
Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am. 2006;37(1):35–51.
Hu P, Zhao L, Zhang H, Yu X, Wang Z, Ye Z, et al. Recurrence rates and risk factors for primary giant cell tumors around the knee: a multicentre retrospective study in China. Sci Rep. 2016;6:36332.
Schütte HE, Taconis WK. Giant cell tumor in children and adolescents. Skeletal Radiol. 2004;22:173–6.
Hoch B, Inwards C, Sundaram M, Rosenberg AE. Multicentric giant cell tumor of bone Clinicopathologic analysis of thirty cases. J Bone Joint Surg Am. 2006;88(9):1998–2008.
Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134(9):969–78.
Vult von Steyern F, Bauer HC, Trovik C, Kivioja A, Bergh P, Holmberg Jörgensen P, et al. Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing A Scandinavian Sarcoma Group study. J Bone Joint Surg Br. 2006;88(4):531–5.
Lin X, Liu J, Xu M. The prognosis of giant cell tumor of bone and the vital risk factors that affect its postoperative recurrence: a meta-analysis. Transl Cancer Res. 2021;10(4):1712–22.
Machak GN, Snetkov AI. The impact of curettage technique on local control in giant cell tumour of bone. Int Orthop. 2021;45(3):779–89.
Omlor GW, Lange J, Streit M, Gantz S, Merle C, Germann T, et al. Retrospective analysis of 51 intralesionally treated cases with progressed giant cell tumor of the bone: local adjuvant use of hydrogen peroxide reduces the risk for tumor recurrence. World J Surg Oncol. 2019;17(1):73.
Algawahmed H, Turcotte R, Farrokhyar F, Ghert M. High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic review and meta-analysis. Sarcoma. 2010; 2010
Lin F, Hu Y, Zhao L, Zhang H, Yu X, Wang Z, et al. The epidemiological and clinical features of primary giant cell tumor around the knee: a report from the multicenter retrospective study in china. J Bone Oncol. 2016;5(1):38–42.
Ambrosi F, Righi A, Benini S, Magagnoli G, Chiaramonte I, Manfrini M, et al. Giant cell tumor of bone in patients under 16 years old: a single-institution case series. Cancers (Basel). 2021; 13(11)
Dahlin DC, Cupps RE, Johnson EW Jr. Giant-cell tumor: a study of 195 cases. Cancer. 1970;25(5):1061–70.
Clarke JON. Oxford textbook of orthopaedics and trauma. Ulster Med J. 2006;75(3):236–7.
Wang Q, Zhang Y, Zhang E, Xing X, Chen Y, Nie K, et al. A multiparametric method based on clinical and CT-based radiomics to predict the expression of p53 and VEGF in patients with spinal giant cell tumor of bone. Front Oncol. 2022;12:894696.
Han YH, Gao B, Huang JH, Wang Z, Guo Z, Jie Q, et al. Expression of CD147, PCNA, VEGF, MMPs and their clinical significance in the giant cell tumor of bones. Int J Clin Exp Pathol. 2015;8(7):8446–52.
Lujic N, Sopta J, Kovacevic R, Stevanovic V, Davidovic R. Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67. Int Orthop. 2016;40(11):2393–9.
Cheng DD, Hu T, Zhang HZ, Huang J, Yang QC. Factors affecting the recurrence of giant cell tumor of bone after surgery: a clinicopathological study of 80 cases from a single center. Cell Physiol Biochem. 2015;36(5):1961–70.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
IRB approval was obtained for this study (Pro00109180).
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Level of Evidence: III—Retrospective Cohort Study
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tabarestani, T.Q., Levine, N., Sachs, E. et al. Giant cell tumor of bone in the pediatric population: a retrospective study highlighting cases of metaphyseal only location and increased local recurrence rates in skeletally immature patients. Skeletal Radiol 52, 2399–2408 (2023). https://doi.org/10.1007/s00256-023-04359-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00256-023-04359-8